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 Dear Editor, 
Mucous membrane pemphigoid (MMP) is an autoimmune mucosal scarring disease having severe 
ocular morbidity (1). Disease susceptibility is associated with increased frequencies of HLA-
DQB1*03:01, HLA-DRB1*11 and HLA-DRB1*04 and decreased frequencies of DQB1*02 (2). To 
explore correlations between clinical involvement and HLA-class-II alleles, we prospectively 
phenotyped a cohort of 55 British MMP patients, and 41 age/sex matched controls (Ethics approval 
reference 09/H0721/54).  
 Inclusion criteria have been described (3) and were pre-agreed clinical criteria with or 
without a positive direct immunofluorescence (DIF) study. HLA-typing used allele specific 
sequencing protocols (Protrans S3 HLA-DRB1* and HLA-DQB1* Cyclerstrips, Protrans, 
Hockenheim, Germany). Statistical analysis used Fisher’s exact test (p), with Benjamini-Hochberg 
correction (pc) defined as significant when pc < 0.05.  
 The study dataset, with clinical and laboratory results, is provided in Table and Legend S1. 
Fifteen patients, 14 of them with ocular involvement, were DIF-negative of whom 7 had antibodies 
to basement membrane zone epitopes. MMP affected sites varied: 8 were ocular only, 10 oral only, 
15 oral and ocular only and 22 multisite. Exons 2 and 3 in HLA-DQB1 were fully analysed in 54/55 
patients and 39/41 controls (Table 1a). The frequency of HLA-DQB1*03:01 was increased (pc = < 
0.01) in 36/54 (67%) of MMP patients (13 homozygous and 23 heterozygous) compared to 13/39 
(33%) controls (2 homozygous and 11 heterozygous, Table 1a). Exon 2 of HLA-DRB1 was also 
fully analysed in 54/55 patients and 40/41 controls; HLA-DRB1*03:01 was decreased (p = < 0.01, 
pc = 0.045, Table 1b). Additionally, we compared the frequency of HLA-DQB1*0301 with controls 
for different sites of involvement showing that HLA-DQB1*0301 was increased in all subgroups 
except for ocular only MMP. Compared to controls, DIF-positive MMP had significantly increased 
HLA-DQB1*0301 (p = 0.00009) but this difference was not significant for either DIF-negative 
MMP (p=0.113) or for DIF-positive ocular only MMP. 
  Some studies have described a correlation of HLA-DQB1*03:01 with ocular and oral MMP 
or in ocular only MMP, whereas others have shown HLA-DQB1*03:01 to be associated with 
multisite MMP (2). In this study the association of HLA-DQB1*0301 with MMP was lower than in 
the largest reported study (2) (pc < 0.00000028), possibly due to our inclusion of 8 patients without 
detectable tissue-bound or serum antibodies, who were excluded from the latter study (2). In ocular 
only MMP 50% are DIF negative but have a phenotype that both progresses and responds to 
therapy in the same way as DIF positive cases (3,4). DIF-negative ocular MMP may result from 
inadequate test sensitivity, because of the small volumes of tissue involved, to dominance of an 
autoreactive T cell mediated over a autoantibody mediated disease (4) or because this is a different 
disease subset. We included our DIF-negative cases because to leave these out of this analysis 
disregards a group of cases which do not fit criteria for any other disease. 
In our prospectively characterized cohort the association with HLA-DQB1*0301, HLA-
DQB1*02, and HLA-DRB1*11 was corroborated whereas HLA-DRB1*0301 was identified as a 
potentially protective allele which requires confirmation in a larger study.  
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 Table 1a 
 
 
HLA-DQB1 
patients controls p-value pc (n=54) in % (n=39) in % 
HLA-DQB1*02 9 16.6 18 46.2 < 0.01 < 0.01 
HLA-DQB1*03 48 88.9 20 51.3 < 0.01 < 0.01 
HLA-DQB1*04 4 7.4 6 15.4 0.31 0.39 
HLA-DQB1*05 13 24 11 28.2 0.81 0.81 
HLA-DQB1*06 13 24 18 46.2 0.04 0.07 
 
HLA-DQB1*02 
HLA-DQB1*02:01 6 11.1 9 23.1 0.15 n. d. 
HLA-DQB1*02:02 3 5.5 7 17.9 0.09 n.d. 
 
HLA-DQB1*03 
HLA-DQB1*03:01 36 66.6 13 32.1 < 0.01 0.01 
HLA-DQB1*03:02 7 13 2 5.1 0.29 0.63 
HLA-DQB1*03:03 4 7.4 2 5.1 1 1 
HLA-DQB1*03:05 0 0 1 2.6 0.42 0.63 
HLA-DQB1*03:19 1 1.8 0 0 1 1 
HLA-DQB1*03:22 0 0 1 1.3 0.42 0.63 
 
 Table 1b 
 
HLA-DRB1 patients controls p-value pc (n=54) in % (n=39) in % 
HLA-DRB1*01 10 18.5 12 30 0.23 0.48 
HLA-DRB1*0301¹ 7 13 15 37.5 < 0.01 0.046 
HLA-DRB1*04 20 37 7 17.5 0.04 0.15 
HLA-DRB1*05 0 0 1 2.5 0.43 0.59 
HLA-DRB1*07 5 9.3 10 25 0.05 0.14 
HLA-DRB1*08 3 5.5 4 10 0.45 0.59 
HLA-DRB1*09 3 5.5 0 0 0.27 0.48 
HLA-DRB1*11 25 40.7 7 17.5 < 0.01 0.046 
HLA-DRB1*12 3 5.5 1 2.5 0.63 0.75 
HLA-DRB1*13 13 24 6 17.5 0.31 0.5 
HLA-DRB1*14 1 1.8 0 0 1 1 
HLA-DRB1*15 9 16.6 14 35 0.05 0.14 
HLA-DRB1*16 1 1.8 0 0 1 1 
 
HLA-DRB1*11 
HLA-
DRB1*11:01/11:97 12 22.2 5 12.5 0.29 n. d. . 
HLA-DRB1* 
11:01/11:97  
or 11:04 
2 3.7 0 0 0.5 n. d.. 
HLA-DRB1*11:02 
or 11:36 or 11:48 1 1.85 0 0 1 n. d. 
HLA-DRB1*11:03 2 3.7 0 0 0.5 n. d. 
HLA-DRB1*11:03 
or 11:11 2 3.7 0 0 0.5 n. d. 
HLA-DRB1*11:04 6 11.1 2 5 0.46 n. d.. 
Table 1a: Distribution of HLA-DQB1 among patients and controls 
Table 1b: Distribution of HLA-DRB1 among patients and controls 
 
In the first step of the analysis the gene frequencies for the allel groups of HLA-DQB1 (2 - 6) and 
HLA-DRB1 (1, 3-5, 7- 9, and 11-16) were compared and in the second step, only significant alleles 
were further analysed  regarding specific HLA-protein (e. g. HLA-DRB1*11) and compared. The p-
value is given for comparisons of HLA gene frequencies, between cases and controls, using Fishers 
Exact test for each allele. The Pc value is the probability value after  
using the Benjamini-Hochberg correction for multiple testing. 
 
n. d. not done 
¹ all patients with HLA-DRB1*03 expressed the specific protein HLA-DRB1*0301
 
